David Shaw’s Organon & Co OGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.73M Sell
718,753
-1,925,799
-73% -$23M ﹤0.01% 1833
2026
Q1
$15.8M Sell
2,644,552
-742,172
-22% -$5.58M 0.01% 1299
2025
Q4
$24.3M Buy
3,386,724
+2,895,864
+590% +$22.9M 0.01% 1130
2025
Q3
$5.24M Buy
+490,860
New +$4.82M ﹤0.01% 2172
2024
Q4
Sell
-140,486
Closed -$2.29M 4732
2024
Q3
$2.69M Buy
+140,486
New +$2.91M ﹤0.01% 2465
2024
Q1
Sell
-182,619
Closed -$3.13M 4617
2023
Q4
$2.63M Buy
+182,619
New +$2.48M ﹤0.01% 2455
2023
Q3
Sell
-13,150
Closed -$274K 4416
2023
Q2
$274K Buy
+13,150
New +$286K ﹤0.01% 3635
2023
Q1
Sell
-27,836
Closed -$777K 4738
2022
Q4
$777K Sell
27,836
-95,593
-77% -$2.44M ﹤0.01% 3611
2022
Q3
$2.89M Sell
123,429
-184,848
-60% -$5.58M ﹤0.01% 2674
2022
Q2
$10.4M Buy
308,277
+102,023
+49% +$3.57M 0.01% 1360
2022
Q1
$7.2M Sell
206,254
-656,859
-76% -$22.5M 0.01% 1929
2021
Q4
$26.3M Buy
863,113
+76,102
+10% +$2.48M 0.02% 901
2021
Q3
$25.8M Sell
787,011
-357,455
-31% -$11.4M 0.02% 866
2021
Q2
$34.6M Buy
+1,144,466
New +$37.7M 0.03% 727

Other funds holding OGN

David Shaw's OGN Position: Q2 2026 in Review

David Shaw reduced its Organon & Co (OGN) stake by 73% in Q2 2026, selling an estimated $23M and leaving 718,753 shares worth $9.73M. The position accounts for ﹤0.01% of the portfolio, ranked #1833.

David Shaw first reported a position in OGN in Q2 2021 and has held it in 14 quarters since. The position peaked at $34.6M in Q2 2021. 627 funds tracked by Wall St. Rank hold OGN as of Q2 2026.

  • David Shaw held 718,753 shares of Organon & Co worth $9.73M as of Q2 2026.
  • David Shaw sold 1,925,799 Organon & Co shares in Q2 2026, an estimated $23M.
  • Organon & Co made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #1833 holding.
  • David Shaw first reported a position in Organon & Co in Q2 2021 and has held it in 14 quarters since.
  • David Shaw's Organon & Co position peaked at $34.6M in Q2 2021.
  • 627 funds tracked by Wall St. Rank held Organon & Co as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.